Get the Stockscreener App
12.60
0.94%
-0.12
After Hours:
12.60
Bicara Therapeutics Inc stock is traded at $12.60, with a volume of 194.00K.
It is down -0.94% in the last 24 hours and down -19.18% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$12.72
Open:
$13.84
24h Volume:
194.00K
Relative Volume:
0.48
Market Cap:
$685.64M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.40%
1M Performance:
-19.18%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.28
$13.91
1-Week Range:
$11.76
$13.91
52-Week Range:
$11.10
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-785-8308
Address
245 MAIN STREET, CAMBRIDGE
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
12.60 | 685.64M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowTime to Sell? - MarketBeat
Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright - MSN
Stifel maintains Buy on Bicara stock with $47 target By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 at HC Wainwright - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up After Analyst Upgrade - Defense World
Bicara reports positive Phase 1/1b trial results for cancer therapy By Investing.com - Investing.com South Africa
Bicara reports positive Phase 1/1b trial results for cancer therapy - Investing.com Nigeria
Bicara Therapeutics Presents Phase 1/1b Dose Expansion - GlobeNewswire
Stifel maintains Buy on Bicara stock with $47 target - Investing.com India
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up on Analyst Upgrade - MarketBeat
H.C. Wainwright lifts Bicara stock target to $45, maintains buy By Investing.com - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 - MarketBeat
Cantor Fitzgerald Weighs in on BCAX FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on BCAX FY2025 Earnings - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average Price Target from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Barclays PLC Purchases Shares of 10,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Initiates Corporate Presentation on Promising Corporate Strategy - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 4.1%Here's What Happened - MarketBeat
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Geode Capital Management LLC Buys Shares of 48,639 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Geode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Jane Street Group LLC Makes New $309,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Reuters
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year LowWhat's Next? - MarketBeat
Barclays PLC Takes $255,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9%What's Next? - MarketBeat
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Most important biotech stories of 2024: IPOs, M&A deals and more layoffs - The Business Journals
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):